Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis

doi:10.3748/wjg.119693

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 42

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 14, 2026; 32(42): 119693
Published online Nov 14, 2026. doi: 10.3748/wjg.119693

Table 4 Steroid-free remission by prior biologic failure, median (interquartile range)/n (%)

Prior biologic failed¹	Number of prior therapies	Steroid-free remission 6 months	Steroid-free remission 12 months
Vedolizumab	4 (3-4)	10 (30.3)	4 (30.8)
Ustekinumab	3 (2-3)	43 (41.5)	14 (36.8)
Upadacitinib	4 (3-5)	4 (26.7)	1 (16.7)

¹Steroid-free remission rates according to prior biologic therapy exposure.

Full Size Table

Citation: Caballero-Mateos AM, Valdés-Delgado T, Olmedo-Martín R, Romero-Cara P, Martín-Rodríguez MDM, Lancho Muñoz A, Moreno-Barrueco M, Gijón-Villanova R, Fernández-Moreno N, Rodríguez-González FJ, Hernández-Martínez Á, Trapero-Martínez AM, Bejarano-García A, Benitez Cantero JM, Mata-Perdigón FJ, Sáez-Díaz A, Argüelles-Arias F. Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis. World J Gastroenterol 2026; 32(42): 119693
URL: https://www.wjgnet.com/1007-9327/full/v32/i42/119693.htm
DOI: https://dx.doi.org/10.3748/wjg.119693

Caballero-Mateos AM, Valdés-Delgado T, Olmedo-Martín R, Romero-Cara P, Martín-Rodríguez MDM, Lancho Muñoz A, Moreno-Barrueco M, Gijón-Villanova R, Fernández-Moreno N, Rodríguez-González FJ, Hernández-Martínez Á, Trapero-Martínez AM, Bejarano-García A, Benitez Cantero JM, Mata-Perdigón FJ, Sáez-Díaz A, Argüelles-Arias F. Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis. World J Gastroenterol 2026; 32(42): 119693 [DOI: 10.3748/wjg.119693]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.